\u00abJo augst\u0101ka lati\u0146a, jo lab\u0101k. T\u0101 m\u0113s str\u0101d\u0101jam,\u00bb intervij\u0101 \u017eurn\u0101lam “Forbes” saka Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js un l\u012bdz\u012bpa\u0161nieks Kirovs Lipmans. Vi\u0146\u0161 uzskata, ka viens no galvenajiem uz\u0146\u0113muma veiksmes faktoriem ir koncentr\u0113\u0161an\u0101s uz ilgtermi\u0146a att\u012bst\u012bbu. Grindeks ir liel\u0101kais farm\u0101cijas uz\u0146\u0113mums Baltijas valst\u012bs, bet tas negu\u013c uz lauriem. Uz\u0146\u0113muma att\u012bst\u012bb\u0101 p\u0113d\u0113jo desmit gadu laik\u0101 invest\u0113ti vair\u0101k nek\u0101 60 miljoni eiro.<\/p>\n\n\n\n
S\u0101cis teju pirms 70 gadiem ar sojas m\u0113r\u010du un me\u017eroz\u012b\u0161u s\u012brupu ra\u017eo\u0161anu, \u0161odien Grindeks ir Eiropas l\u012bme\u0146a farm\u0101cijas uz\u0146\u0113mums ar diviem ori\u0123in\u0101lproduktiem un vair\u0101k nek\u0101 100 gatavo z\u0101\u013cu formu.<\/p>\n\n\n\n
Kad 1957. gad\u0101 Latvijas Zin\u0101t\u0146u akad\u0113mijas Organisk\u0101s sint\u0113zes instit\u016bts izveidoja eksperiment\u0101lo r\u016bpn\u012bcu, taj\u0101 tika s\u0101kta \u0101rstniec\u012bbas vielu ra\u017eo\u0161ana. Jau tad speci\u0101listi s\u0101ka str\u0101d\u0101t pie pretv\u0113\u017ea prepar\u0101tiem, un \u0161is darbs rezult\u0113j\u0101s ar akt\u012bvo vielu ftoraf\u016bru \u2013 instit\u016bta un r\u016bpn\u012bcas sadarb\u012bbas liel\u0101ko veiksmi, kuru septi\u0146desmitajos gados s\u0101ka pieg\u0101d\u0101t Jap\u0101nas r\u016bpn\u012bc\u0101m. Ftoraf\u016brs\u00ae<\/small><\/em> \u0101tri ieguva labu slavu, un tagad tas ir viens no Grindeks visvair\u0101k eksport\u0113tajiem produktiem.<\/p>\n\n\n\n Desmit gadus v\u0113l\u0101k aizs\u0101k\u0101s darbs pie r\u016bpn\u012bcas otra paz\u012bstam\u0101k\u0101 produkta Mildron\u0101ta\u00ae<\/small><\/em> \u2013 prepar\u0101ta sirds un asinsvadu slim\u012bbu \u0101rst\u0113\u0161anai. Latvijai atg\u016bstot neatkar\u012bbu, eksperiment\u0101l\u0101 r\u016bpn\u012bca k\u013cuva par valsts uz\u0146\u0113mumu Grindeks, bet 1997. gad\u0101, nosl\u0113dzoties privatiz\u0101cijas procesam \u2013 par publisko akciju sabiedr\u012bbu. Kop\u0161 2002. gada uz\u0146\u0113muma galvenais akcion\u0101rs ir Kirovs Lipmans.<\/p>\n\n\n\n L\u012bdz \u0161odienai uz\u0146\u0113muma apgroz\u012bjums ir desmitk\u0101r\u0161ojies, bet pe\u013c\u0146a palielin\u0101jusies teju vai se\u0161desmit rei\u017eu. P\u0113d\u0113jo desmit gadu laik\u0101 uz\u0146\u0113mum\u0101 invest\u0113ti vair\u0101k nek\u0101 60 miljoni eiro, izveidotas jaunas ra\u017eotnes un cehi. \u0160ogad liel\u0101k\u0101s invest\u012bcijas 2,3 miljonu eiro apm\u0113r\u0101 atv\u0113l\u0113tas kvalit\u0101tes kontroles laboratorijas pilnveidei. Par uz\u0146\u0113muma augsto l\u012bmeni liecina sa\u0146emtie kvalit\u0101tes, p\u0101rvald\u012bbas un labas ra\u017eo\u0161anas prakses sertifik\u0101ti, k\u0101 ar\u012b Jap\u0101nas, ASV un citu valstu instit\u016bciju sniegtie atzinumi, ka Grindeks ra\u017eot\u0101s produkcijas kvalit\u0101te atbilst pasaules standartiem. Tas \u013cauj uz\u0146\u0113mumam eksport\u0113t savu produkciju uz 55 pasaules valst\u012bm \u2013 liel\u0101koties Krieviju un p\u0101r\u0113j\u0101m NVS valst\u012bm, turkl\u0101t 13 valst\u012bs uz\u0146\u0113mumam ir savas p\u0101rst\u0101vniec\u012bbas.<\/p>\n\n\n\n Konkurence farm\u0101cijas biznes\u0101 ir s\u012bva, it \u012bpa\u0161i Krievijas un NVS valstu tirgos. \u201eGatavo z\u0101\u013cu formu jom\u0101 tur m\u0113s saskaramies ar iev\u0113rojamu viet\u0113jo ra\u017eot\u0101ju protekcionismu,\u00bb situ\u0101ciju skaidro Lipmans. Tas ir galvenais Grindeks gatavo z\u0101\u013cu z\u0101\u013cu formu noieta tirgus, jo taj\u0101 uz\u0146\u0113mums realiz\u0113 pusi produkcijas, t\u0101d\u0113\u013c vad\u012bba tur roku uz pulsa. Pagaid\u0101m gan nav par ko uztraukties, jo Krievijas farm\u0101cijas tirgus uzr\u0101da pozit\u012bvas pieauguma tendences.<\/p>\n\n\n\n Savuk\u0101rt akt\u012bvo farmaceitisko vielu biznes\u0101 galvenie konkurenti ir \u0136\u012bnas un Indijas ra\u017eot\u0101ji, kas piekopj zemo cenu politiku. Lai nezaud\u0113tu savas poz\u012bcijas, Grindeks liek liet\u0101 savas zin\u0101\u0161anas sare\u017e\u0123\u012btu, daudzpak\u0101pju sint\u0113z\u0113 izstr\u0101d\u0101tu vielu ra\u017eo\u0161an\u0101. \u00abL\u012bdz\u0161in\u0113j\u0101 izaugsme apliecina, ka m\u0113s varam sekm\u012bgi konkur\u0113t ar citiem ra\u017eot\u0101jiem, t\u0101p\u0113c, neskatoties ne uz ko, es n\u0101kotn\u0113 raugos ar ap\u0146\u0113m\u012bbu,\u00bb saka Kirovs Lipmans.<\/p>\n\n\n\n Uz\u0146\u0113mums ar\u012b regul\u0101ri papildina savu produktu kl\u0101stu \u2013 katru gadu pl\u0101nots ieviest \u010detrus patentbr\u012bvos produktus. Tie ir analogi medikamenti ori\u0123in\u0101lajiem produktiem, kas tirg\u016b var par\u0101d\u012bties, tikl\u012bdz beidzies patents ori\u0123in\u0101lajiem prepar\u0101tiem. Tom\u0113r, lai l\u012bdz tam tiktu, ir j\u0101iziet vair\u0101ki posmi, s\u0101kot ar pacientu un \u0101rstu viedok\u013cu apkopojumu, beidzot ar p\u0113t\u012bjumiem un invest\u012bcij\u0101m.<\/p>\n\n\n\n Katra produkta pievienot\u0101 v\u0113rt\u012bba ir taj\u0101 ieguld\u012bt\u0101s zin\u0101\u0161anas. Grindeks ir sava p\u0113tniec\u012bbas un att\u012bst\u012bbas strukt\u016bra, kas da\u013cu darba veic pa\u0161u sp\u0113kiem, bet da\u013cai tiek piesaist\u012bti viet\u0113jie un \u0101rvalstu zin\u0101tniskie un p\u0113tnieciskie centri. Par p\u0113tniec\u012bbas noz\u012bmi uz\u0146\u0113mum\u0101 var spriest p\u0113c ieguld\u012btajiem l\u012bdzek\u013ciem \u2013 katru gadu tie ir vair\u0101k nek\u0101 pieci miljoni eiro. \u201eM\u0113s str\u0101d\u0101jam ar\u012b jaunu ori\u0123in\u0101lo produktu izp\u0113tes un izstr\u0101des jom\u0101, turkl\u0101t ar redzamiem rezult\u0101tiem,\u201d skaidro Lipmans. Latvijas Zin\u0101t\u0146u akad\u0113mija izteikusi atzin\u012bbu Latvijas Organisk\u0101s sint\u0113zes instit\u016bta un Grindeks<\/em> zin\u0101tniekiem, par vienu no noz\u012bm\u012bg\u0101kajiem pag\u0101ju\u0161aj\u0101 gada sasniegumiem zin\u0101tnes praktiskaj\u0101 pielietojum\u0101 nosaucot jaunas z\u0101\u013cu vielas \u0137\u012bmisk\u0101s un eksperiment\u0101l\u0101s izp\u0113tes pabeig\u0161anu. \u00abTas \u013caus uzs\u0101kt vielas kl\u012bniskos p\u0113t\u012bjumus, un tas noz\u012bm\u0113, ka n\u0101kotn\u0113 var tapt jauns sirds un asinsvadu grupas medikaments,\u00bb atkl\u0101j Kirovs Lipmans. Tom\u0113r jaunu ori\u0123in\u0101lo produktu izstr\u0101de ir \u013coti sare\u017e\u0123\u012bts process un var pras\u012bt pat miljardu eiro lielas invest\u012bcijas.<\/p>\n\n\n\n T\u0101 k\u0101 Latvij\u0101 v\u0113rojams t\u0101 d\u0113v\u0113tais brain drain<\/em> \u2013 talant\u012bgo un gudro cilv\u0113ku do\u0161an\u0101s prom no valsts, Grindeks sav\u0101 nozar\u0113 cen\u0161as pret to nodro\u0161in\u0101ties. Kop\u0161 2006. gada uz\u0146\u0113mums nodibin\u0101jis fondu Zin\u0101tnes un izgl\u012bt\u012bbas atbalstam<\/em>, un ik gadu t\u0101 atbalstu sa\u0146em cilv\u0113ki, kas ir apliecin\u0101ju\u0161i izcil\u012bbu da\u017e\u0101d\u0101s Latvijas izgl\u012bt\u012bbas un zin\u0101tnes jom\u0101s, k\u0101 ar\u012b projekti, kas sekm\u0113 zin\u0101tnes un izgl\u012bt\u012bbas att\u012bst\u012bbu. Turkl\u0101t Grindeks ir Latvijas hokeja izlases \u0123ener\u0101lsponsors un Operas patrons. Papildus tam uz\u0146\u0113mums t\u0113r\u0113 teju 15% no apgroz\u012bjuma m\u0101rketinga aktivit\u0101t\u0113m da\u017e\u0101du valstu tirgos, lai virz\u012btu savus produktus. Pag\u0101ju\u0161\u0101 gada pirmajos devi\u0146os m\u0113ne\u0161us tie vien jau bija 11 miljoni eiro.<\/p>\n\n\n\n \u00abFarm\u0101cijas biznes\u0101 ir j\u0101str\u0101d\u0101 t\u0101, lai pl\u0101nus, idejas, ieceres var\u0113tu zin\u0101t ne tikai \u0161im gadam, bet daudziem gadiem uz priek\u0161u,\u00bb pieredz\u0113 dal\u0101s Lipmans. \u0160\u0137iet, ka Grindeks vad\u012bbai m\u0113r\u0137i ir skaidri.<\/p>\n\n\n\n \u201cFarm\u0101cijas l\u012bderis\u201d, \u017eurn\u0101ls \u201eForbes\u201d 2014. gada febru\u0101ris<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" \u00abJo augst\u0101ka lati\u0146a, jo lab\u0101k. T\u0101 m\u0113s str\u0101d\u0101jam,\u00bb intervij\u0101 \u017eurn\u0101lam “Forbes” saka Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js un l\u012bdz\u012bpa\u0161nieks Kirovs Lipmans. Vi\u0146\u0161 uzskata, ka viens no galvenajiem…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1387"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1387\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}